Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Lysodren (mitotane)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Perrigo Company

Drug class:

Steroid receptor inhibitor

Related drugs:

‹

›

No biomarker	Adrenal Cortex Carcinoma	No biomarker	Adrenal Cortex Carcinoma	mitotane Sensitive: A1 - Approval mitotane Sensitive : A1	mitotane Sensitive: A1 - Approval mitotane Sensitive : A1
No biomarker	Adrenal Cortex Carcinoma	No biomarker	Adrenal Cortex Carcinoma	cisplatin + doxorubicin hydrochloride + etoposide IV + mitotane Sensitive: A2 - Guideline cisplatin + doxorubicin hydrochloride + etoposide IV + mitotane Sensitive : A2	cisplatin + doxorubicin hydrochloride + etoposide IV + mitotane Sensitive: A2 - Guideline cisplatin + doxorubicin hydrochloride + etoposide IV + mitotane Sensitive : A2
No biomarker	Adrenal Cortex Carcinoma	No biomarker	Adrenal Cortex Carcinoma	carboplatin + etoposide IV + mitotane Sensitive: A2 - Guideline carboplatin + etoposide IV + mitotane Sensitive : A2	carboplatin + etoposide IV + mitotane Sensitive: A2 - Guideline carboplatin + etoposide IV + mitotane Sensitive : A2
No biomarker	Adrenal Cortex Carcinoma	No biomarker	Adrenal Cortex Carcinoma	carboplatin + doxorubicin hydrochloride + etoposide IV + mitotane Sensitive: A2 - Guideline carboplatin + doxorubicin hydrochloride + etoposide IV + mitotane Sensitive : A2	carboplatin + doxorubicin hydrochloride + etoposide IV + mitotane Sensitive: A2 - Guideline carboplatin + doxorubicin hydrochloride + etoposide IV + mitotane Sensitive : A2
No biomarker	Adrenal Cortex Carcinoma	No biomarker	Adrenal Cortex Carcinoma	cisplatin + etoposide IV + mitotane Sensitive: A2 - Guideline cisplatin + etoposide IV + mitotane Sensitive : A2	cisplatin + etoposide IV + mitotane Sensitive: A2 - Guideline cisplatin + etoposide IV + mitotane Sensitive : A2
No biomarker	Adrenal Cortex Carcinoma	No biomarker	Adrenal Cortex Carcinoma	mitotane + streptozocin Sensitive: A2 - Guideline mitotane + streptozocin Sensitive : A2	mitotane + streptozocin Sensitive: A2 - Guideline mitotane + streptozocin Sensitive : A2
RRM1 underexpression	Adrenal Cortex Carcinoma	RRM1 underexpression	Adrenal Cortex Carcinoma	mitotane Sensitive: C3 – Early Trials mitotane Sensitive : C3	mitotane Sensitive: C3 – Early Trials mitotane Sensitive : C3
TMB-L	Adrenal Cortex Carcinoma	TMB-L	Adrenal Cortex Carcinoma	mitotane Sensitive: C3 – Early Trials mitotane Sensitive : C3	mitotane Sensitive: C3 – Early Trials mitotane Sensitive : C3
AURKB overexpression	Adrenal Cortex Carcinoma	AURKB overexpression	Adrenal Cortex Carcinoma	mitotane + AMG 900 Sensitive: D – Preclinical mitotane + AMG 900 Sensitive : D	mitotane + AMG 900 Sensitive: D – Preclinical mitotane + AMG 900 Sensitive : D
AURKA overexpression	Adrenal Cortex Carcinoma	AURKA overexpression	Adrenal Cortex Carcinoma	mitotane + AMG 900 Sensitive: D – Preclinical mitotane + AMG 900 Sensitive : D	mitotane + AMG 900 Sensitive: D – Preclinical mitotane + AMG 900 Sensitive : D